Bimeda is pleased to announce the appointment of David Cunningham to the role of Chief Commercial Officer for North America. Cunningham’s appointment is effective from January 1, 2018, and his role will focus on the provision of strategic leadership to the U.S. and Canadian business operations.
As a 30 year veteran in animal health, Cunningham brings a wealth of relevant experience to the role, having held an impressive range of high-level assignments in sales, marketing and executive leadership for several leading U.S. animal health companies. These included the position of Executive Vice President of Sales and Marketing at AgriLabs, Vice President of Sales and Marketing at Boehringer-Ingelheim Vetmedica, and President & CEO at Teva Animal Health. For the past three years, he has worked as Chief Operating Officer for Axxiom Consulting; a leading provider of executive consulting services to the animal health industry.
Cunningham commented that, “The animal health market is undergoing profound changes in both the livestock and companion animal segments. At this pivotal time for the industry I am excited to join Bimeda and provide strategic leadership to build on Bimeda’s success to date, as well as identifying and capitalizing on new growth opportunities throughout North America.”
Cunningham will report directly to Gavin Tierney, Group Chief Operating Officer & CEO Americas and Europe, who added; “Bimeda is on the fast track to becoming a premier provider of animal health and brand alternative products in the United Stated. Dave will be instrumental in guiding our commercial operations to strategically seize new business opportunities.”
Bimeda Inc, North America
Cunningham’s appointment is the latest in a series of significant developments within the Bimeda North America business, and follows on from strategic acquisitions last year within the equine animal health sector. These included the purchase of equine company ArthroDynamic, as well as the acquisition of several prominent equine products from CEVA Animal Health.
With half a century’s experience in the manufacture, distribution and marketing of veterinary pharmaceuticals and animal health products, Bimeda is a well-established global presence in the veterinary pharmaceutical industry.
Since its foundation in Ireland in the mid 1960s, the company’s impressive growth has seen them achieve a truly global footprint; with Bimeda now boasting a presence in over 75 countries, across 6 continents.
Bimeda’s vast product offering covers both livestock and companion animals, and includes products from a broad array of therapeutic classes.
Bimeda’s manufacturing capabilities are enviable, with 10 manufacturing facilities in 7 countries; all operating to the highest regulatory standards. The company manufactures numerous dosage forms, with the capacity for both sterile and non-sterile production.
While Bimeda’s customer-focused culture and an ethos of continuous improvement ensure customers’ current needs and expectations are routinely surpassed, their global R&D programme is committed to anticipating the future needs of the animal health sector. Bimeda’s continued investment in its five state-of-the-art laboratories across four continents is demonstrative of the company’s commitment to serving the future needs of the global animal health market.
Bimeda and its employees remain committed to the company ethos of Global Excellence in Animal Health and to providing animal health professionals and companion animal owners with the products and services which promote optimum animal health and productivity.
For more information on Bimeda, visit www.bimeda.com.